21 November 2017
News and Views
Links and Services
Trastuzumab with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastroesophageal junction cancer, reports a study in The Lancet.
Trastuzumab is a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors